Observations from the OMERACT Drug Safety Summit, May 2008.
Due to mounting concern about determination of benefit and risk in the context of product development and clinical practice the OMERACT Executive identified the need to bring together a variety of specialists to define risk. At the Drug Safety Summit held at OMERACT 9, specialists spoke on their given topics and the group considered risk in the context of formally posed questions.
Simon
Lee S
LS
Harvard Medical School, Boston, MA, USA. omeract@uottawa.ca
Strand
C Vibeke
CV
Boers
Maarten
M
Brooks
Peter M
PM
Henry
David
D
Tugwell
Peter S
PS
D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D055808:Drug Discovery; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D012216:Rheumatic Diseases / Q000188:drug therapy*; D018570:Risk Assessment
D018501:Antirheumatic Agents